Orexin receptor antagonism for treatment of insomnia
A randomized clinical trial of suvorexant
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 5, 2012
- Accepted July 30, 2012
- First Published November 28, 2012.
Article Versions
- Previous version (November 28, 2012 - 17:14).
- You are viewing the most recent version of this article.
Author Disclosures
- W. Joseph Herring, MD, PhD,
- Ellen Snyder, PhD,
- Kerry Budd, BS,
- Jill Hutzelmann, MS,
- Duane Snavely, MA,
- Kenneth Liu, PhD,
- Christopher Lines, PhD,
- Thomas Roth, PhD and
- David Michelson, MD
- W. Joseph Herring, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Merck, Executive Director Clinical Neuroscience
NONE
NONE
NONE
NONE
Employee of Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Own stock and stock options in Merck
NONE
- Ellen Snyder, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
(1) Merck, Senior Principal Scientist, Biostatistics
NONE
NONE
NONE
NONE
Employee of Merck & Co., Inc.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Own stock and stock options in Merck.
NONE
- Kerry Budd, BS,
NONE
NONE
NONE
NONE
NONE
NONE
Merck, Clinical Scientist
NONE
NONE
NONE
NONE
Employee of Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Own stock options at Merck
NONE
- Jill Hutzelmann, MS,
NONE
NONE
NONE
NONE
NONE
NONE
Merck, Sr. Clinical Scientist
NONE
NONE
NONE
NONE
Yes, employee of Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Merck stock/stock options, 1990 to present
NONE
- Duane Snavely, MA,
NONE
NONE
NONE
NONE
NONE
NONE
Merck, Director of Late Development Statistics
NONE
NONE
NONE
NONE
Employee of Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Own stock, and stock options in Merck
NONE
- Kenneth Liu, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Merck, Senior Principal Scientist, Biostatistics.
NONE
NONE
NONE
NONE
Employee of Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Own stock and stock options at Merck
NONE
- Christopher Lines, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Merck, Director Global Scientific and Medical Publications
NONE
NONE
NONE
NONE
Employee of Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Own stock and stock options in Merck
NONE
- Thomas Roth, PhD and
Merk, Jazz, Transcept,
NONE
NONE
Sleep, Sleep Medicine
NONE
NONE
NONE
Roth has served as a consultant for Abbott, Accadia, Acogolix, Acorda, Actelion, Addrenex, Alchemers, Alza, Ancel, Arena, AstraZenca, Aventis, AVER, Bayer, BMS, BTG, Cephalon, Cypress, Dove, Eisai, Elan, Eli Lilly, Evotec, Forest, Glaxo Smith Kline, Hypnion, Impax, Intec, Intra-Cellular, Jazz, Johnson and Johnson, King, Ludbeck, McNeil, MediciNova, Merck, Neurim, Neurocrine, Neurogen, Novartis, Orexo, Organon, Otsuka, Prestwick, Proctor and Gamble, Pfizer, Purdue, Resteva, Roche, Sanofi, SchoeringPlough, Sepracor, Servier, Shire, Somaxon, Syrex, Takeda, TransOral, Yanda, Vivometrics, Wyeth, Yamanuchi, and Xenoport
Purdue
NONE
NONE
Transcept, Impax, Linguflex, Apnes
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Michelson, MD
NONE
NONE
NONE
NONE
NONE
NONE
Merck Employee
NONE
NONE
Merck stockholder
Merck employee, Merck would market the drug if approved by regulatory authorities
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Stock and stock options in Merck
NONE
NONE
- From Merck Sharp & Dohme Corp. (W.J.H., E.S., K.B., J.H., D.S., K.L, C.L, D.M.), Whitehouse Station, NJ; and Henry Ford Hospital Sleep Center (T.R.), Detroit, MI.
- Correspondence & reprint requests to Dr. Herring: william.herring{at}merck.com
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorderGary Zammit, Yves Dauvilliers, Scott Pain et al.Neurology, April 27, 2020 -
Article
Association of CSF orexin-A levels and nocturnal sleep stability in patients with hypersomnolenceLucie Barateau, Régis Lopez, Sofiene Chenini et al.Neurology, September 01, 2020 -
Articles
Sleep disturbance and melatonin levels following traumatic brain injuryJ.A. Shekleton, D.L. Parcell, J.R. Redman et al.Neurology, May 24, 2010 -
Articles
Restless legs syndrome improved by pramipexoleA double-blind randomized trialJacques Montplaisir, Alain Nicolas, Régine Denesle et al.Neurology, March 01, 1999